Speakers Introduction

Highly qualified computational drug discovery scientist with core expertise in the areas of quantum information, artificial intelligence, computational biology, and multi-omics. The position of Head of AI Research at Milner Therapeutics of University of Cambridge would come with a remit to lead frontier AI and quantum technology applications for the analysis of complex multimodal biomedical datasets. This will be instrumental in the discovery of new disease pathways and mechanisms. In parallel to these roles at Milner, I also hold an appointment as a Faculty at the Cambridge Centre for AI in Medicine and an Affiliated Principal Investigator at the Cambridge Stem Cell Institute. In my academic contributions, I also serve as a Professor at the Department of Quantum Information, Yonsei University.

Further to this field of academic sciences, I am also engaged in linking the gap of academic research and its use in industrial use, more in-depth in the field of therapeutics and patient care. I eagerly look forward to the possibilities AI brings to revolutionize disease identification, discovery of drug targets, and indeed very wide scope in patient care, just to ensure our industrial collaborators are well-placed in these advances. It will allow me to develop creative computational strategies common to us both in our grand goal of new therapeutic solutions via the analysis of big data. In addition to these positions, I have also served the scientific function of founding Storm Therapeutics. I am also a co-founder of two high innovative AI drug discovery start-ups: Kure.ai Therapeutics in the field of developing immunotherapies with NK cells and CardiaTec Biosciences to bring forward therapeutics for revolutionary cardiological patients.